COMPARISON OF EFFICIENCY AND SAFETY Of CO-DIROTON, ENALAPRIL AND HYDROCHLOROTHIAZIDE IN PSORIATIC PATIENTS WITH ARTERIAL HYPERTENSION AND OVERWEIGHT


Дәйексөз келтіру

Толық мәтін

Аннотация

Recent studies indicate a definite relationship of psoriasis and cardiovascular diseases. The article presents the results of study, which was aimed to evaluation of efficacy and safety of Co-Diroton, a fixed low-dose combination of lisinopril and hydrochlorothiazide (HCT) as compared with enalapril and hydrochlorothiazide in 83 psoriatic patients with arterial hypertension (AH) 1-2 degree and overweight . It was shown that administration of enalapril 10 mg/day, HCT 25 mg/day, or Co-Diroton 10/12.5 mg in this group of patients is safe, well tolerated and accompanied by a significant decrease in blood pressure (BP) without reducing the effectiveness of antipsoriatic therapy. Thus, Co-Diroton had significantly more antihypertensive effect than enalapril or hydrochlorothiazide as monotherapy: against the background of its use significantly more patients achieved target BP levels (83 vs 48 and 44 %).

Әдебиет тізімі

  1. National Psoriasis Foundation. Psoriasis statistics. Доступно в сети Интернет по адресу: http://www.psoriasis.org Последнее обращение: 06.12.2010.
  2. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis. Arch Dermatol 2007;143:1493-99.
  3. Nakagami T, Qiao Q, Tuomilehto J, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006;13(4):555-61.
  4. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16(5-6):319-23.
  5. Gelfand JM, Feldman SR, Stern RS, et al. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-08.
  6. Qureshi АA, Choi HK, Setty AR, et al. Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses. Arch Dermatol 2009;145(4):379-82.
  7. Nakagami T, Qiao Q, Tuomilehto J, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006;13(4):555-61.
  8. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 2005;16(5-6):319-23.
  9. Kim GK, Del Rosso JQ. Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? Understanding Pathophysiology and Clinical Relevance. J Clin Aesthet Dermatol 2010;3(1):32-38.
  10. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
  11. Адаскевич В.П. Диагностические индексы в дерматологии. Медицинская книга. М., 2004. С.107-108.
  12. Kimball AB, Gladman D, Gelfand JM, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
  13. Dratelin CR, Martinez-Abundis E, Balcazar-Munoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003;48:882-85.
  14. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33-39.
  15. Дворянкова Е.В., Шевченко А.О., Шевченко О.П., Новосельцев М.В., Орлова О.В., Гинзбург Л.М. Эффективность и безопасность симвастатина у больных распространенным псориазом // Дальневосточный вестник дерматовенерологии, косметологии и пластической хирургии. 2010. №1 (7). С. 22-26.
  16. Gelfand JM, Feldman SR, Stern RS, et al. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-08.
  17. Ravipati G, Aronow WS, Ahn C, et al. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up inpatients with diabetes mellitus, hypertension or both with and without microalbuminuria. Cardiology 2008;109(1):62-65.
  18. Gibson SH, Perry HO. Diabetes and psoriasis. AMA Arch Derm 1956;74(5):487-88.
  19. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216(2):152-55.
  20. Ravipati G, Aronow WS, Ahn C, et al. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up in patients with diabetes mellitus, hypertension or both with and without microalbuminuria. Cardiology 2008;109(1):62-65.
  21. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35.
  22. Qureshi АA, Choi HK, Setty AR, et al. Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses. Arch Dermatol 2009;145(4):379-82.
  23. Al-Awadhi AM, Hasan EA, Sharma PN, et al. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol Int 2007;27(12):1119-23.
  24. Huskic J, Alendar F. Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosn J Basic Med Sci 2007;7(2):103-06.
  25. Rodgers K, Xiong S, Felix J, et al. Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen 2001;9:238-47.
  26. Moscarelli L, Zanazzi M, Mancini G, et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol 2010;73(6):439-45.
  27. Шевченко А.О., Шевченко О.П. Фиксированная низкодозовая комбинация лизиноприла и гидрохлортиазида в профилактике сердечно-сосудистых событий у больных артериальной гипертонией // Рациональная фармакотерапия в кардиологии. 2010. № 6(5). C. 697-702.
  28. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996;156(17):1969-78.
  29. Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:6.
  30. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. JRAAS 2002;3:72-8
  31. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>